FitzPatrick Margaret M purchased $12K of ANTX
FitzPatrick Margaret M purchased 2,098 shares of AN2 Therapeutics, Inc. (ANTX) at $5.53 on 2026-09-01.
How this was made
The 30-second read
Why it matters
The purchase adds modest confidence but is unlikely to move the stock.
Market read
Low relevance; typical insider transaction with limited trading implication.
What to watch
Potential upcoming clinical milestones not disclosed.
Background
Form 4 filing by a director of AN2 Therapeutics, a US-listed biotech company.
Ticker impact
Director Margaret FitzPatrick purchased 2,098 shares of ANTX for $11,602, increasing her holding to 10,708 shares.
Minimal short-term price movement expected.
The transaction size is modest relative to market cap and does not constitute a significant ownership change.
Market effects
None significant for biotech sector.
No regional impact.
Limited to ANTX shareholders.
Counterpoint
Insider buying could be a subtle bullish signal despite small size.
Key entities
- CompanyAN2 Therapeutics, Inc.
Biotech firm developing therapeutics.
- InsiderMargaret FitzPatrick
Director of AN2 Therapeutics.